No Data
No Data
HTSC: Different performance for beauty and medical beauty in Q2. Q3 may be more challenging for new product sales during off-season.
In Q3 24, it is the off-season for the industry, but also an important window period for many brand manufacturers to prepare for the November 11 shopping festival. It is recommended to pay close attention to new product developments.
Hong Kong stock concept tracking| The surgical robot industry is developing rapidly, and institutions are paying attention to investment opportunities brought by updates to medical devices (attached with concept stocks).
The global surgical robot market is expected to reach $28.51 billion by 2025, with a compound annual growth rate of 27.1% from 2021 to 2025.
Fosun Pharma Announces Merger Delay
Fosun Pharma Receives Offers for Share Alternative Offer Related to Henlius Merger Offer
Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) received offers for a potential share alternative offer in relation to its merger offer for Shanghai Henlius Biotech (HKG:2696),
BofA Merrill Lynch is bullish! Raised the target price of Fosun Pharma's (02196) H shares to 17 yuan, accelerating innovation and transformation to achieve results.
Recently, international investment bank Morgan Stanley released its latest research report and raised the target price for Fosun Pharma's H shares from the original HKD 16 to HKD 17, indicating a potential increase of over 25% from the current H share price. It also maintained a 'shareholding' rating for Fosun Pharma, and predicted that the compound annual growth rates of the company's pharmaceutical, equipment, and hospital businesses' revenue from 2023 to 2025 will reach 8%, 13%, and 10%, respectively. This forecast reflects the strong growth momentum of core pharmaceutical sales, particularly in biosimilars and innovative drugs.
Fosun Pharma Advances Towards Henlius Privatization
No Data